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ABSTRACT 
Over the last few decades, the inclusions of peptide drugs in the pharmaceutical formulation aspects are more contemporary and recurrent. 
Since peptide moieties for the treatment of various clinical conditions has been started worthwhile since 1930’s. There has been an increasingly 
sustainable research work regarding the formulation of therapeutic peptides are in the arena, as probably several entities are already in the 
clinical investigation, whereas few more are in the pipeline for clinical indication. In this current discussion, it has been aimed to unleash the 
potential of therapeutic bioactive peptides and its future prospects, in the area of pharmaceutical formulation. A plinth of area in regard to the, 
demand for the development of pharmaceutical formulation of bioactive peptides are still need to be uncovered. And hence only we have 
discussed deeply about the contemporary prospects of the peptide moieties.  
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INTRODUCTION 
Numerous prospects of biopharmaceutical process 
development have been well examined over the past few 
decades. Complicatedness in fermentation, cell culture, and, 
to some extent, purification and recovery has largely been 
conquered and these process steps have been well 
characterized for the production of a lot of protein 
pharmaceuticals. Conversely, one important field lags behind 
these others in its development. The design and production 
of protein and peptide drug formulations is not well 
developed and many of the mechanisms for stabilization and 
delivery of these drugs are significant1. 
  
 
Figure 1: Current Scenario in peptide drug development 
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Peptides are recognized for being highly selective and 
efficacious and, at the same time, relatively safe and well 
tolerated. Consequently, there is an increased interest in 
peptides in pharmaceutical research and development 
(R&D), and approximately 140 peptide therapeutics are 
currently being evaluated in clinical trials. Given that the 
low-hanging fruits in the form of obvious peptide targets 
have already been picked, it has now become necessary to 
explore new routes beyond traditional peptide design. 
Examples of such approaches are multifunctional and cell 
penetrating peptides, as well as peptide drug conjugates2-4. 
Here, we discuss the current status, strengths, and 
weaknesses of peptides as medicines and the emerging new 
opportunities in peptide drug design and development as 
mentioned in Fig 1. 
  
 
 
Figure 2: Pharmaceutical applications of Bioactive peptides 
 
Proteins and peptides play important roles in living body 
systems by controlling, directing and/or coordinating inter- 
and intra-cellular communications and cellular function. 
From a nutritional perspective, peptides are more 
bioavailable than proteins or free amino acids. Further, 
peptides with low molecular weight have been known to be 
less allergenic than their native proteins, explaining why 
milk protein hydrolysates are widely utilized in the 
formulation of hypoallergenic infant foods. Additionally, as 
nature’s tool kit; the diverse physiological roles of peptides 
make them suitable candidates for the development of 
therapeutic agents. There is a wide variety of physiological 
activities induced by bioactive peptides and these 
bioactivities are determined by the type, number, sequence 
and properties of amino acids present in the peptide. It is 
worth mentioning that whereas some proteins (such as 
lysozyme and α-lactalbumin) retain their bioactivities even 
the unhydrolysed denatured state, usually, the 
aforementioned bioactivities are latent until proteins are 
hydrolysed to release physiologically active peptides shown 
in Fig 2. Captured are some bioactive peptides and their 
bioactivities or areas of therapeutic applications. Bioactive 
peptides are therefore suitable candidates for a new era of 
pharmaceutical products, especially with the heightened 
concerns of side effects of small molecule drugs and the 
increased attention to fresher and ‘greener’ foods and 
nutraceuticals possessing health-preventing or health-
promoting properties. 
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Marketed products and its clinical implications of Peptide drugs5-8 
Brand Name  Common 
Name 
Chemical Name Intended purpose 
Eraxis, Ecalta Anidulafungin 1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-
tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl- 
2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22hexaazatricyclo 
[22.3.0.09,13]heptacosan-18-yl]-4-{4-[4-(pentyloxy) 
phenyl] phenyl}benzamide 
Antifungal drugs that inhibits 
the synthesis of 1,3-β-D-glucan 
Antocin Atosiban 
acetate 
c[Mpa-Tyr(Et)-Ile-Thr-Asn-Cys]-Pro-Orn-Gly-NH2,acetate 
[or [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin ,acetate] 
Delaying the birth in case of 
threat of premature birth 
Bacitracin, 
Cortisporin, 
Neosporin 
Bacitracin 1-(N-((2-(1-amino-2-methylbutyl)-4,5-dihydro- 
4-thiazolyl)carbonyl)-L-leucine) 
Infants with pneumonia and 
empyema caused by 
staphylococci 
Angiomax Bivalirudin H-D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-
Glu-Glu-Ile-Pro-Glu-Glu-Tyr- Leu-OH, trifluoroacetate 
hydrate 
Anticoagulant in patients with 
unstable angina undergoing 
PTCA or PCI 
Velcade Bortezomib Pyz-Phe-boroLeu-(OH)2 Multiple myeloma, and 
refractory, mantle cell 
lymphoma 
Bigonist Buserelin Pyr-His-Trp-Ser-Tyr-D-Ser(OtBu)-Leu-Arg-Pro-NHEt (or 
N-ethyl-prolinamide), acetate 
Advanced prostate cancer 
Miacalcin Calcitonin Cys-Gly-Asn-Leu-Ser-Thr-Cys-Met-Leu-Gly- Thr-Tyr-Thr-
Gln-Asp-Phe-Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ala-
Ile-Gly-Val-Gly-Ala-Pro-NH2 
Symptomatic Paget's disease 
for patients unresponsive to 
alternate treatments or 
intolerant to such treatments 
Duratocin Carbetocin 
acetate 
c[Tyr(Me)-Ile-Gln-Asn-Cys((CH2)3CO2-)]-Pro-Leu-Gly-
NH2, acetate 
Prevention of uterine atony, 
induction,and control 
postpartum bleeding or  
haemorrhage 
Cancidas Caspofungin 5-((2-Aminoethyl)amino)-N(2)-(10,12-dimethyl 
tetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-
hydroxy-L-prolyl--4-hydroxy-4-(P- hydroxyphenyl)-L-
threonyl-threo-3-hydroxy-Lornithyl-trans-3-hydroxy-L-
proline cyclic (6-1)-peptide 
Antifungal drug 
Capoten Captopril 2-Methyl-3sulfanylpropanoyl]pyrrolidine-2-carboxylic 
acid 
Renovascular hypertension 
Cetrotide Cetrorelix 
acetate 
Ac-D-2Nal-D-4-chloroPhe-D-3-(3´ - pyridyl)Ala-Ser-Tyr-D-
Cit-Leu-Arg-Pro-D-Ala-NH2, acetate 
Inhibition of premature LH 
surges in women undergoing 
controlled ovarian stimulation 
Colomycin, 
Coly-Mycin, 
Promixin. 
Colistin 
 
6,9,18-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-12,15-
bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-
1,4,7,10,13,16,19-heptaazacyclotricosan-21-
yl]carbamoyl}propyl]carbamoyl}-2-hydroxypropyl] 
carbamoyl}propyl]-5-methylheptanamide 
Acute or chronic infections due 
to sensitive strains of certain 
gram negative bacilli, 
Gengraf, 
Neoral, 
Pulminiq, 
Restasis, 
Sandimmune 
Cyclosporine Cyclic(L-alanyl-D-alanyl-N-methyl-L-leucyl-Nmethyl- 
L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl- L-2-
amino-6-octenoyl-L-alphaamino-butyryl-N-methylglycyl-
N-methyl-Lleucyl-L-valyl-N-met hyl-L-leucyl) 
Transplant (kidney, liver, and 
heart) rejection, rheumatoid 
arthritis, severe psoriasis. 
Cosmegen Dactinomycin 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-
bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1- 
I)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-
dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide. 
Wilms'tumor, childhood 
rhabdomyosarcoma, Ewing's 
sarcoma and metastatic 
Firmagon Degarelix 
acetate 
Ac-D-2Nal-D-4-chloroPhe-D-3-(3´ -pyridyl)Ala-Ser-4-
aminoPhe(L-hydroorotyl)-D-4-aminoPhe(carbamoyl)-Leu-
isopropylLys-Pro-D-Ala-NH2, acetate 
Advanced prostate cancer 
Cubicin Daptomycin N-Decanoyl-L-tryptophyl-L-asparaginyl-Laspartyl- 
L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-
aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-
anthraniloyl-Lalanine[egr]1-lactone 
Complicated skin and skin 
structure infections caused by 
susceptible strains of Gram-
positive microorganisms. 
Fuzeon Enfuvirtide Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu- 
Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu- 
Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala- 
Ser-Leu-Trp-Asn-Trp-Phe-NH2 
AIDS/HIV-1 infection 
Vasotec Enalapril 
maleate 
(S)-1-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]- 
Ala]-Pro-OH, maleate or (Z)-2-butenedioate 
Hypertension 
Integrilin Eptifibatide c[Mpa-homoArg-Gly-Asp-Trp-Pro-Cys]-NH2 Acute coronary syndrome, 
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unstable angina undergoing 
PCI 
Byetta Exenatide H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-
Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-
Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 
[Incretinmimetics (GLP-1 et GIP)] 
Glycemic control in patients 
with type 2 diabetes mellitus 
Agifutol Glutathione H-g-Glu-Cys-Gly-OH Hepatic insufficiency, wound 
healing, inflammation of 
respiratory tract, asthenia 
Zoladex Goserelin Pyr-His-Trp-Ser-Tyr-D-Ser(OtBu)-Leu-Arg-Pro-AzGly-NH2, 
acetate [or [DSer(OtBu)6,AzGly10]GnRH, acetate] 
Advanced prostate cancer, 
breast cancer 
Cibacalcin Human 
calcitonin 
H-c[Cys-Gly-Asn-Leu-Ser-Thr-Cys]-Met-Leu-Gly-Thr-Tyr-
Thr-Gln-Asp-Phe-Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-
Ala-Ile-Gly-Val-Gly-Ala-Pro-NH2 
Postmenopausal osteoporosis, 
Paget’s disease, 
hypercalcaemia 
Firazyr Icatibant 
acetate 
H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH, 
acetate 
Hereditary angioedema 
Somatuline 
Depot 
Ianreotide 
acetate 
H-2Nal-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2,acetate Acromegaly, carcinoid 
syndrome 
Refludan Lepirudin or 
r-hirudin 
H-Leu-Thr-Tyr-Thr-Asp-Cys-Thr-Glu-Ser-Gly-Gln-Asn-Leu-
Cys-Leu-Cys-Glu-Gly-Ser-Asn-Val-Cys-Gly-Gln-Gly-Asn-Lys-
Cys-Ile-Leu-Gly-Ser-Asp-Gly-Glu-Lys-Asn-Gln-Cys-Val- 
Thr-Gly-Glu-Gly-Thr-Pro-Lys-Pro-Gln-Ser-His-Asn-Asp-
Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH 
For the treatment of heparin-
induced thrombocytopenia 
Liraglutide Victoza H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val- 
Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-N6-[N-(1-
oxohexadecyl)-L-g-Glu]-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-
Arg-Gly-Arg-Gly-OH [GLP-1analogue] 
Type 2 diabetes 
Zestril, 
Prinivil 
Lisinopril (S)-1-[N2-(1-carboxy-3-phenylpropyl)-Lys]-Pro-OH Hypertension,congestive heart 
failure 
Diapid Lypressin H-c[Cys-Tyr-Phe-Gln-Asn-Cys]-Pro-Lys-Gly-NH2 [or 8-L-
lysinevasopressine] 
Central diabetes insipidus, 
Cushing’s syndrome 
Synarel Nafarelin 
acetate 
Pyr-His-Trp-Ser-Tyr-2Nal-Leu-Arg-Pro-Gly-NH2, acetate Central precocious puberty, 
endometriosis, uterine fibroids, 
ovarian stimulation in in vitro 
fecundation 
Natrecor Nesiritide Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-[Cys-Phe-Gly-Arg- 
Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-leu-Gly-Cys]- Lys-
Val-Leu-Arg-Arg-His-OH 
Acutely decompensated 
congestive heart failure who 
have dyspnea at rest or with 
minimal activity. 
Sandostatin Octreotide H-D-Phe-c[Cys-Phe-D-Trp-Lys-Thr-Cys]-Thol,acetate Acromegaly, carcinoid 
syndrome 
Syntocinon Oxytocin H-c[Cys-Tyr-Ile-Gln-Asn-Cys]-Pro-Leu-Gly-NH2  Initiation or improvement 
of uterine contractions, and 
control postpartum bleeding or 
haemorrhage 
Fortical Salmon 
calcitonin 
H-c[Cys-Ser-Asn-Leu-Ser-Thr-Cys]-Val-Leu-Gly-Lys-Leu-
Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-
Asn-Thr-Gly-Ser-Gly-Thr-Pro-NH2 
Postmenopausalosteoporosis, 
Paget’sdisease, hypercalcaemia 
 
Saralasin 
acetate 
Sarenin H-Sar-Arg-Val-Tyr-Val-His-Pro-Ala-OH, acetate[1-Sarcosyl-
8-Alanyl-angiotensin II] 
Hypertension 
Stilamin Somatostatin 
acetate 
H-Ala-Gly-c[Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr- Phe-Thr-
Ser-Cys]-OH, acetate 
Acute variceal bleeding 
Rhinaaxia Spaglumat 
magnesium 
Ac-Asp-Glu-OH, magnesium or sodium salt Allergic rhinitis and 
conjunctivitis 
Zadaxin Thymalfasin Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glulle-Thr-Thr-
Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-
Asn-OH 
Chronic hepatitis B, chronic 
hepatitis C 
Aggrastat Tirofiban 2-(butylsulfonylamino)-3-[4-(4-piperidin-4-
ylbutoxy)phenyl]propanoic acid 
Acute coronary syndrome 
Octastatin, 
Sanvar 
Vapreotide 
acetate 
H-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp-NH2, acetate Esophageal Variceal Bleeding 
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Peptide is low and/or high molecular weight biopolymers, 
which acquiesce two or more amino acid on hydrolysis. 
Peptides are the standard constituent of the protoplasm of 
cells and are high molecular weight compounds comprising 
of alpha amino acid adjoined together by peptide linkages. 
These proteins serve as enzymes, structural element, 
hormones or immunoglobulin and are concerned in 
metabolic process, cell augmentation, immunogenic defense 
mechanisms and other genetic activities9. 
Peptides proteins are an significant class of biological 
material which are not only the necessary nutrients of 
human body, but some of the polypeptide hormones like 
insulin are used in treating an assortment of diseases 
consequential from hormonal deficiency. As this use of 
peptides for systemic handling of certain diseases is well 
accepted in medical practice, research activities are being 
directed towards the production of huge quantities by rDNA 
expertise. 
Mainly common route of administration for protein drug 
delivery has been parenteral, although many other routes 
have been tried with varying degree of accomplishment. 
Routes likely, intraocular, rectal, vaginal pulmonary and 
intranasal mode will bring the drug to the systemic 
circulation while avoiding transit through the digestive 
system. A major factor that restricts the usefulness of these 
substances for their intended therapeutic function is that 
they are simply metabolized by plasma proteases when they 
arrive at the peripheral circulation. Besides, adverse effects 
connected with are relevant these drugs to the pulmonary or 
the other mucosal surfaces may be preventive10-12. 
Delivering therapeutically active protein by the oral route 
has been confronted and a goal for many years. For such 
drugs to be absorbed during the gastrointestinal tract, they 
must be protected from enzyme and must cross during the 
luminal barriers into the blood stream in an unchanged 
shape.  
CONCLUSION 
In this context, there has been a substantial potential for the 
development of peptide drugs, there has been an everlasting 
demand for various ailments and illness. However, to 
unleash the clinical implications of peptide drugs are in great 
need in recent times. And so only in this review the various 
aspects of peptide drugs currently in the market and those 
approved by the international authorities are also been 
discussed.  
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